Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins
Theravance Raises $225m In Royalty Sale To GSK
Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.
